Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 27, 2012

Agilent Secures Aurora SFC’s Assets

  • Agilent Technologies acquired the assets of Aurora SFC Systems, which provides supercritical fluid chromatography (SFC) products for lab research and analysis. The acquisition includes the Aurora SFC Systems product line as well as intellectual property.

    Aurora SFC Systems has been working with Agilent for the past two years. Aurora's Fusion A5 platform is embedded into Agilent's SFC and Hybrid SFC/UHPLC systems, and is also sold as part of an upgrade option to Agilent's 1100, 1200, and 1260 Series LC systems. Acquiring the Aurora SFC assets now enables Agilent to offer these products as fully integrated, single-vendor SFC solutions, according to Patrick Kaltenbach, vp and general manager of Agilent's liquid phase separations business.

    "The deployment of orthogonal separation techniques has gained significant importance in liquid phase separations as regulatory agencies increasingly demand comprehensive results," added Kaltenbach.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »